- Home
- NML vs VALN Comparison
NML vs VALN Comparison
Compare NML & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NML | VALN |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 497.5M | 537.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NML | VALN |
|---|---|---|
| Price | $10.34 | $6.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 191.1K | 137.0K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 9.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.70 | $5.43 |
| 52 Week High | $10.71 | $12.25 |
Technical Indicators
Market Signals| Indicator | NML | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 56.14 | 27.55 |
| Support Level | $8.38 | N/A |
| Resistance Level | $10.44 | $6.73 |
| Average True Range (ATR) | 0.25 | 0.28 |
| MACD | -0.04 | -0.10 |
| Stochastic Oscillator | 62.67 | 2.46 |
Price Performance
Historical ComparisonAbout NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.